CTLA4 and colonic neoplasm: Similarly, in the colon cancer model, the combination of vistusertib, an mTOR inhibitor, and anti-CTLA-4, an immune checkpoint blockade, increased the cytotoxic activity of intratumoral CD8+ T cells, by the production of molecules such as IFN-γ and granzyme B [43].